Despite decades of medical progress, HIV continues to devastate Black communities. The statistics are sobering. The disparities, undeniable.

This was the stock's second consecutive day of gains.

Among its other ratings, Gilead's Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks. In addition to its excellent Composite Rating, Gilead ...

The largest group of Black physicians, thought leaders, and celebrities were in one room to have a needed discussion about HIV.

An advocacy group is suing the Trump administration for failing to disclose details of a settlement with Gilead over patent ...

Gilead Sciences, Inc. has announced that it has received new approval from the U.S. Food and Drug Administration (FDA) for a ...

AbbVie, Gilead Sciences and GSK marked World Hepatitis Day on Monday, outlining the need to tackle the stigma and ...

Now, it’s worth noting Stock Advisor’s total average return is 1,041% — a market-crushing outperformance compared to 183 % ...

Shares of Gilead Sciences Inc. GILD slid 2.15% to $112.29 Thursday, on what proved to be an all-around rough trading session ...

Similarly, Gilead has provided nearly $35.8 million in total philanthropic support for Black women-led and/or Black ...

Gilead Sciences is expected to announce its fiscal second-quarter earnings next month, and analysts forecast a single-digit ...